The use of free radical scavengers for protecting and treating skin and hair damages caused by chemotherapy

Details for Australian Patent Application No. 2006243223 (hide)

Owner Coty Prestige Lancaster Group GmbH

Inventors Zastrow, Leonhard; Golz-Berner, Karin

Agent Griffith Hack

Pub. Number AU-B-2006243223

PCT Pub. Number WO2006/117405

Priority 10 2005 021 804.0 04.05.05 DE; 10 2005 023 497.6 18.05.05 DE

Filing date 4 May 2006

Wipo publication date 9 November 2006

Acceptance publication date 29 April 2010

International Classifications

A61K 47/02 (2006.01) Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives - Inorganic compounds

A61K 45/08 (2006.01) Medicinal preparations containing active ingredients not provided for in groups

A61K 47/40 (2006.01) Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives - Cyclodextrins

A61K 47/46 (2006.01) Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives - Ingredients of undetermined constitution or reaction products thereof

A61P 17/00 (2006.01) Drugs for dermatological disorders

A61P 17/14 (2006.01) Drugs for dermatological disorders

Event Publications

3 January 2008 PCT application entered the National Phase

  PCT publication WO2006/117405 Priority application(s): WO2006/117405

29 April 2010 Application Accepted

  Published as AU-B-2006243223

26 August 2010 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2006243231-Production of polymers in a conical reactor

2006243218-Use of low doses of oligonucleotides antisense to TGF-beta, VEGF, interleukin-10, c-jun, c-fos or prostaglandin E2 genes in the treatment of tumors